CP
ZYME icon

Castleview Partners’s Zymeworks ZYME Stock Holding History

Castleview Partners’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,219
Closed -$130K – 943
2024
Q2 		$130K Sell
15,219
-10,365
-41% -$92.3K 0.07% 216
2024
Q1 		$269K Buy
+25,584
New +$284K 0.15% 149

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Castleview Partners's ZYME Position: Q3 2024 in Review

Castleview Partners sold out of Zymeworks (ZYME) in Q3 2024, closing a stake of 15,219 shares — an estimated $130K sold.

Castleview Partners first reported a position in ZYME in Q1 2024 and held it in 2 quarters. The position peaked at $269K in Q1 2024. 163 funds tracked by Wall St. Rank hold ZYME as of Q3 2024.

  • Castleview Partners reported no remaining Zymeworks position as of Q3 2024 after selling out during the quarter.
  • Castleview Partners sold 15,219 Zymeworks shares in Q3 2024, an estimated $130K.
  • Castleview Partners first reported a position in Zymeworks in Q1 2024 and held it in 2 quarters.
  • Castleview Partners's Zymeworks position peaked at $269K in Q1 2024.
  • 163 funds tracked by Wall St. Rank held Zymeworks as of Q3 2024.

Based on Castleview Partners's 13F filing for Q3 2024, filed 9 Oct 2024.